How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,081 results for

Sublingual Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Sublingual immunotherapy for treating adult patients with allergic rhinitis induced by house dust mite among Chinese Han population: A retrospective study. (PubMed)

Sublingual immunotherapy for treating adult patients with allergic rhinitis induced by house dust mite among Chinese Han population: A retrospective study. The objective of this retrospective study was to evaluate the efficacy and safety of sublingual immunotherapy (SLIT) for treating adult patients with allergic rhinitis (AR) induced by house dust mite (HDM) among Chinese Han population.A total of 201 adult patients with AR induced by HDM were included. All of them received SLIT treatment

Full Text available with Trip Pro

2018 Medicine

62. Role of Interleukin-35 in sublingual allergy immunotherapy. (PubMed)

Role of Interleukin-35 in sublingual allergy immunotherapy. Grass pollen-specific immunotherapy involves immunomodulation of allergen-specific TH2 responses and induction of IL-10+ and/or TGF-β+CD4+CD25+ regulatory T cells (induced Treg cells). IL-35+CD4+CD25+ forkhead box protein 3-negative T (IL-35-inducible regulatory T [iTR35]) cells have been reported as a novel subset of induced Treg cells with modulatory characteristics.We sought to investigate mechanisms underlying the induction (...) allergy (seasonal allergic rhinitis [SAR] group, n = 16), sublingual immunotherapy (SLIT)-treated patients (SLIT group, n = 16), and nonatopic control subjects (NACs; NAC group, n = 16).The SAR group had increased proportions of ILC2s (P = .002) and IL-5+ cells (P = .042), IL-13+ cells (P = .042), and IL-5+IL-13+ ILC2s (P = .003) compared with NACs. IL-35 inhibited IL-5 and IL-13 production by ILC2s in the presence of IL-25 or IL-33 (P = .031) and allergen-driven TH2 cytokines by effector T cells. IL

Full Text available with Trip Pro

2018 Journal of Allergy and Clinical Immunology

63. Allergen-specific sublingual immunotherapy is dose- and duration-dependent in a murine allergic rhinitis model. (PubMed)

Allergen-specific sublingual immunotherapy is dose- and duration-dependent in a murine allergic rhinitis model. 30102936 2018 12 11 1097-6825 142 6 2018 Dec The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Allergen-specific sublingual immunotherapy is dose and duration dependent in a murine allergic rhinitis model. 1977-1979.e9 S0091-6749(18)31137-0 10.1016/j.jaci.2018.08.002 Tofukuji Soichi S Drug Discovery & Disease Research Laboratory, Shionogi & Co, Ltd, Osaka, Japan

2018 Journal of Allergy and Clinical Immunology

64. Sublingual Immunotherapy Tablets Relieve Symptoms in Adults with Allergic Rhinitis: A Meta-analysis of Randomized Clinical Trials (PubMed)

Sublingual Immunotherapy Tablets Relieve Symptoms in Adults with Allergic Rhinitis: A Meta-analysis of Randomized Clinical Trials Sublingual immunotherapy (SLIT) has been proven to be effective against house dust mite-induced allergic rhinitis. However, the efficacy in adults with allergic rhinitis has never been reported on SLIT tablets. The current meta-analysis aimed to illustrate the differentiated efficacy of SLIT tablets on allergic rhinitis.Our systematic review and meta-analysis were

Full Text available with Trip Pro

2018 Chinese medical journal

65. Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study. (PubMed)

Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study. The SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet has demonstrated effective treatment of HDM-induced allergic asthma in patients 18 years or older in European trials. This study investigated its safety and immunology profile in Japanese adult patients with mild

2018 Journal of Asthma

66. A birch sublingual allergy immunotherapy (SLIT) tablet educes rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG<sub>4</sub> to allergens from all trees in the birch homologous group. (PubMed)

A birch sublingual allergy immunotherapy (SLIT) tablet educes rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group. This randomized, double-blind trial was conducted to determine the optimal dose for clinical efficacy of the SQ tree SLIT-tablet. An environmental exposure chamber (EEC) was used to reduce variability of allergen exposure and allow investigation of symptom reduction towards different

Full Text available with Trip Pro

2018 Allergy

67. Sublingual immunotherapy for pediatric allergic conjunctivitis: a meta-analysis of randomized controlled trials. (PubMed)

Sublingual immunotherapy for pediatric allergic conjunctivitis: a meta-analysis of randomized controlled trials. Allergic conjunctivitis (AC) is a common chronic condition, especially in children. Ocular symptoms are often overlooked during treatment of allergic rhinoconjunctivitis (ARC). Pediatric ARC can be effectively treated using sublingual immunotherapy (SLIT), which is a guideline-recommended safe treatment approach. However, the therapeutic efficacy of SLIT in terms of ameliorating eye

2018 International forum of allergy & rhinology

68. Immunologic modification in mono- and poly-sensitized patients after sublingual immunotherapy. (PubMed)

Immunologic modification in mono- and poly-sensitized patients after sublingual immunotherapy. To compare immunologic modification and treatment outcomes after 2 years of sublingual immunotherapy (SLIT) with house dust mite extracts (HDM) between monosensitized and polysensitized patients with allergic rhinitis.Retrospective cohort study.Among the patients who were prospectively enrolled in the SLIT cohort study, patients with allergic rhinitis who were sensitized to HDM and treated with SLIT

2018 Laryngoscope

69. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy. (PubMed)

Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy. Birch pollen-related apple allergy is among the most prevalent food allergies in adolescent/adult subjects and mainly results from sensitization to the major birch pollen allergen Bet v 1 and subsequent cross-reaction with the apple protein Mal d 1. However, specific immunotherapy with birch pollen has inconsistent effects on apple allergy.We (...) sought to compare the safety and efficacy of sublingual immunotherapy (SLIT) with 2 formulations containing either rMal d 1 or rBet v 1 on birch pollen-related apple allergy.Sixty participants with birch pollen-related apple allergy were randomized to daily sublingual application of placebo (n = 20) or 25 μg of rMal d 1 (n = 20) or rBet v 1 (n = 20) for 16 weeks. Adverse events were regularly recorded. Sublingual challenges with standardized doses of rMal d 1, skin prick tests with recombinant

2018 The Journal of allergy and clinical immunology

70. Sublingual immunotherapy for treating allergic conjunctivitis. (PubMed)

Sublingual immunotherapy for treating allergic conjunctivitis. Allergic ocular symptoms, although frequently trivialised, are common and represent an important comorbidity of allergic rhinitis. Sublingual Immunotherapy (SLIT) is an effective and well-tolerated treatment for allergic rhinitis, but its effects on symptoms of ocular allergy have not been well established.To evaluate the efficacy of SLIT compared with placebo for reductions in ocular symptoms, topical ocular medication requirements (...) Review Manager software.Forty-two trials (n = 3958 total participants; n= 2011 SLIT and n = 1947 placebo) had available data to evaluate the efficacy of SLIT on AC and were included in the meta-analyses. Heterogeneity among studies (I(2) statistic) was around 50% or below for all endpoints. Sublingual immunotherapy induced a significant reduction in both total ocular symptom scores (SMD -0.41; 95% confidence interval (CI) -0.53 to -0.28; P < 0.00001; I(2) = 59%) and individual ocular symptom scores

2011 Cochrane

71. [Efficacy of sublingual immunotherapy and subcutaneous immunotherapy in children with allergic rhinitis]. (PubMed)

[Efficacy of sublingual immunotherapy and subcutaneous immunotherapy in children with allergic rhinitis]. Objective:To evaluate the efficacy and safety of sublingual immunotherapy(SLIT) and subcutaneous immunotherapy(SCIT) in children with pediatric allergic rhinitis.Method:This study retrospectively analyzed the efficacy and safety of SLIT and SCIT in 186 children with allergic rhinitis which induced by house dust mites.Patients were randomly divided into two groups:SLIT group consisted of 104

2016 Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery

72. Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study (PubMed)

Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study The majority of allergic patients are poly-sensitized. For causal treatment by allergy immunotherapy (AIT) a single or few allergen products containing the clinically most relevant allergens are applied, but few data on tolerability of multiple application of AIT is available. The aim of our study was to investigate safety (...) and tolerability in patients who started treatment by sublingual immunotherapy (SLIT) with the standardised SQ(®) grass SLIT-tablet and were treated with concomitant AIT products.In a non-interventional, open-label, observational study in Germany treatment of patients with the SQ(®) grass SLIT-tablet and concomitant AIT (SCIT or SLIT) was documented between January 2012 and January 2014. Patients were followed at visits at first administration of the SQ(®) grass SLIT-tablet and after 1-3 months of treatment

Full Text available with Trip Pro

2016 Clinical and translational allergy

73. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. (PubMed)

Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. Recently, a series of assays has been conducted in which sublingual immunotherapy (SLIT) maintenance extracts of European manufacturers were compared with U.S. concentrated extracts by using U.S. Food and Drug Administration recommended in vitro testing. These test results have been published. We herein performed further data analysis to facilitate (...) interpretation of SLIT dosing by U.S. physicians.To express the allergen quantity of maintenance SLIT as recommended by European manufacturers relative to U.S. subcutaneous immunotherapy (SCIT) maintenance dosing.We analyzed the maintenance SLIT solutions of Dermatophagoides pteronyssinus, timothy grass pollen, cat, and ragweed pollen from four European manufacturers and concentrated extracts from three U.S. manufacturers and from the U.S. Food and Drug Administration. Here, we expressed the potency

2016 Allergy and Asthma Proceedings

74. Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. (PubMed)

Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. Sublingual allergen immunotherapy (SLIT) is considered to be safer and more convenient than subcutaneus immunotherapy. SLIT trials with house dust mites involving patients with allergic rhinitis (AR) and asthma reported discordant results. The aim of the study was to investigate the clinical efficacy and safety of SLIT with Dermatophagoides pteronyssinus (D.pt) extract produced in Serbia and patient's

2017 Iranian journal of allergy, asthma, and immunology

75. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. (PubMed)

A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. Treatment with allergy immunotherapy improves allergic rhinoconjunctivitis, but can also improve comorbidities associated with allergic rhinitis such as asthma. Sublingual immunotherapy (SLIT)-tablets are a convenient and efficacious method of allergy immunotherapy. They are self-administered after the first tablet has been provided under medical supervision. Therapy may elicit

2017 Postgraduate medicine

76. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. (PubMed)

Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. Allergy immunotherapy can result in systemic allergic reactions and even life-threatening anaphylaxis requiring epinephrine administration.The objective of this study was to describe epinephrine use in the clinical trial development programs of 3 rapidly dissolving sublingual immunotherapy tablets (SLIT-tablets; Merck & Co., Inc., Kenilworth, NJ/ALK, Hørsholm, Denmark/Torii Pharmaceutical Co., Ltd., Tokyo, Japan).Data

2017 The journal of allergy and clinical immunology. In practice

77. A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis. (PubMed)

A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis. This study was designed to evaluate the efficacy and safety of sublingual immunotherapy (SLIT) with house-dust mite (HDM) extract in Chinese patients with HDM-induced allergic rhinitis (AR).A randomized, double-blind, placebo controlled trial was conducted with the outpatients of the Eye, Ear, Nose, and Throat Hospital, Fudan University. Forty-eight patients were

2017 American journal of rhinology & allergy

78. Could Sublingual Immunotherapy Affect Oral Health in Children with Asthma and/or Allergic Rhinitis Sensitized to House Dust Mite. (PubMed)

Could Sublingual Immunotherapy Affect Oral Health in Children with Asthma and/or Allergic Rhinitis Sensitized to House Dust Mite. Sublingual immunotherapy (SLIT) has been successfully employed in IgE-mediated respiratory allergies. However, it is not known whether the modulation of immune responses in the sublingual area during SLIT has any deleterious effect on oral health. We sought to determine the oral health prospectively in children receiving SLIT for house dust mite allergy.Eighteen

2017 International Archives of Allergy and Immunology

79. The effects of house dust mite sublingual immunotherapy (SLIT)-tablet effects on immunological biomarkers and nasal allergen challenge symptoms. (PubMed)

The effects of house dust mite sublingual immunotherapy (SLIT)-tablet effects on immunological biomarkers and nasal allergen challenge symptoms. 28911971 2018 05 04 1097-6825 141 2 2018 Feb The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms. 785-788.e9 S0091-6749(17)31429-X 10.1016/j.jaci.2017.08.016 Gunawardana Natasha C NC Imperial Clinical

Full Text available with Trip Pro

2017 Journal of Allergy and Clinical Immunology

80. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. (PubMed)

Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. House dust mite (HDM) respiratory allergy is a common and burdensome disease in children and adolescents. There are few HDM allergy immunotherapy trials in children with perennial allergic rhinitis. This post hoc analysis used pooled data to evaluate efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in adolescents (12-17 years).In two double-blind, placebo-controlled

Full Text available with Trip Pro

2017 Pediatric Allergy and Immunology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>